Is MET a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for MetLife (MET) rests on Group Benefits and workplace demand: Group Benefits is a scale business where MetLife sells life, dental, disability, and supplemental coverage through employers. The bear case rests on metLife's biggest risks come from the same levers that drive its profits. Analysts covering it publish targets from $75.00 to $106.00 against a $97.33 price, so even the professionals disagree by 32% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
MetLife, Inc. is one of the world's largest providers of life insurance, employee benefits, annuities, and asset management, serving individuals and institutional clients across the United States, Asia, Latin America, Europe, the Middle East, and Africa. It reports through several segments, including Group Benefits (group life, dental, disability, and other workplace coverage), Retirement and Income Solutions (annuities, pension risk transfers, structured settlements, and stable value products), Asia, Latin America, EMEA, and MetLife Holdings, its book of legacy US business. The core model is classic insurance: collect premiums, pay claims and benefits over time, and invest the difference (the float) in a large fixed-income-heavy portfolio, earning a spread. That makes MetLife both an underwriter and a giant investor, so its profitability depends on disciplined pricing, mortality and morbidity trends, and the returns it earns on invested assets. The investment picture in mid-2026 is one of solid, cash-generative results paired with heavy capital returns. Full-year 2025 revenue rose to about $77.1 billion, though reported net income fell year over year on investment and actuarial items, and adjusted earnings have been trending higher: Q1 2026 adjusted EPS climbed roughly 23% year over year to about $2.42, beating expectations even as reported revenue came in a touch light. Management has emphasized expense discipline (targeting a lower direct expense ratio), strong free cash flow generation, and returning capital: it raised the quarterly dividend by about 4.4% to $0.5925 per share and extended its buyback authorization. MetLife is executing a multi-year strategy focused on growing higher-return businesses like group benefits, retirement solutions, Asia, and asset management while running the legacy Holdings block down.
The bull case: what would have to be true for $106.00
The most optimistic published target on MET is $106.00, +8.9% from the $97.33 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Group Benefits and workplace demand
Group Benefits is a scale business where MetLife sells life, dental, disability, and supplemental coverage through employers. It benefits from steady enrollment, pricing discipline, and cross-selling across large employer relationships. Because these are recurring, contract-based revenues tied to employment and payroll, the segment tends to be more stable than market-sensitive lines, and MetLife's size gives it distribution and underwriting-data advantages over smaller carriers.
2. Retirement and Income Solutions
As populations age and corporations offload pension obligations, MetLife's Retirement and Income Solutions segment writes pension risk transfers, annuities, and structured settlements. Rising or elevated interest rates can improve the spreads it earns on these long-duration liabilities. Demand for guaranteed retirement income and de-risking of corporate pension plans is a structural tailwind, though the business also carries long-tail liability and reinvestment risk.
3. Asia and international growth
MetLife's Asia and Latin America operations target faster-growing, under-insured markets where rising middle-class demand for life and health coverage can outpace mature US growth. These segments diversify the earnings base geographically and can compound over time, though results are exposed to local economic cycles, regulation, and currency movements that add volatility when translated back into US dollars.
4. Capital return and free cash flow
MetLife generates substantial free cash flow and has committed to returning a large share of it through dividends and buybacks. In 2026 it raised its quarterly dividend about 4.4% and extended share repurchases, while targeting expense-ratio improvement and more than $25 billion of free cash flow over its plan period. For a mature insurer, consistent capital return and share-count reduction are central to the total-return case alongside modest underlying growth.
The bear case: what would have to be true for $75.00
The most pessimistic published target is $75.00, -22.9% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks MetLife is worth if the risks below bite instead of the drivers above.
MetLife's biggest risks come from the same levers that drive its profits. As a large investor of policyholder float, it is exposed to interest-rate swings, credit spreads, and equity-market moves: sharp rate changes affect both investment income and the value of long-duration liabilities, and a credit downturn could pressure its bond and commercial-real-estate holdings. Insurance-specific risks include mortality, morbidity, and longevity assumptions proving wrong, plus reserve adequacy on long-tail liabilities like pensions and annuities. Its international earnings add currency and local-regulatory risk. Reported net income can be lumpy because of actuarial assumption updates, derivative marks, and market-related items, which is why the company emphasizes adjusted earnings. Insurance is also heavily regulated and capital-intensive, so statutory capital requirements and rating-agency views constrain how much can be returned to shareholders.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding MET already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on MET
16 analysts cover MET, with an average target of $97.75 (+0.4% against $97.33) and a split of 12 buy, 5 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the MET forecast and price target page.
How is MET valued? (as of Jul 2026)
Snapshot for MET as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue trend: Full-year 2025 revenue was about $77.1 billion, up mid-single digits year over year; Q1 2026 revenue was roughly $19 billion
- Profitability: Adjusted EPS has been rising (Q1 2026 adjusted EPS ~$2.42, up ~23% year over year), while reported net income can swing on investment and actuarial items
- Balance sheet / leverage: Large, mostly fixed-income investment portfolio backing long-duration liabilities; capital-intensive and regulated, with statutory capital and ratings constraints
- Capital returns: Raised the quarterly dividend ~4.4% to $0.5925 per share in 2026 and extended buybacks; targets $25 billion-plus of free cash flow over its plan
- Valuation: Typically trades on a modest earnings multiple and around or below book/embedded value, as is common for large life insurers; verify current P/E and price-to-book live
- Analyst sentiment: Generally constructive on capital return and adjusted-earnings growth, with debate over rate sensitivity and legacy liabilities; check current ratings and targets
These are qualitative and approximate as of the asOf date and not precise real-time figures. Insurer results are heavily affected by interest rates, credit markets, and actuarial assumption changes, so reported numbers can differ sharply from adjusted ones. Confirm live revenue, EPS, dividend, and valuation before acting.
How do you decide if MET is a buy?
Rather than asking whether MET is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MET indirectly through an index or sector ETF before adding more.
What would change your mind on MET
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Group Benefits and workplace demand stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: metLife's biggest risks come from the same levers that drive its profits fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the MET stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MET against your real portfolio and see your actual exposure before deciding.
Investing in MetLife with AI
Connect the broker you already use and ask Walnut's AI how MET fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is MET a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Group Benefits and workplace demand, with revenue trend at Full-year 2025 revenue was about $77.1 billion, up mid-single digits year over year; Q1 2026 revenue was roughly $19 billion. The bear case rests on metLife's biggest risks come from the same levers that drive its profits. Analysts covering it are spread from $75.00 to $106.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell MET?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. MetLife's biggest risks come from the same levers that drive its profits. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $75.00, -22.9% from the $97.33 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for MET?
+
Group Benefits and workplace demand. Group Benefits is a scale business where MetLife sells life, dental, disability, and supplemental coverage through employers. The most optimistic analyst target on MET is $106.00, +8.9% from the $97.33 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for MET?
+
MetLife's biggest risks come from the same levers that drive its profits. As a large investor of policyholder float, it is exposed to interest-rate swings, credit spreads, and equity-market moves: sharp rate changes affect both investment income and the value of long-duration liabilities, and a credit downturn could pressure its bond and commercial-real-estate holdings. Insurance-specific risks include mortality, morbidity, and longevity assumptions proving wrong, plus reserve adequacy on long-tail liabilities like pensions and annuities. Its international earnings add currency and local-regulatory risk. Reported net income can be lumpy because of actuarial assumption updates, derivative marks, and market-related items, which is why the company emphasizes adjusted earnings. Insurance is also heavily regulated and capital-intensive, so statutory capital requirements and rating-agency views constrain how much can be returned to shareholders. The most pessimistic published target is $75.00, -22.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does MetLife do?
+
MetLife, Inc.
What would have to change for MET to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Group Benefits and workplace demand) stalling in the reported numbers rather than in the narrative, the risk above (metLife's biggest risks come from the same levers that drive its profits) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
Is MET a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a large, diversified insurer with strong free cash flow, rising adjusted earnings, a long-standing and growing dividend, and heavy buybacks. The bear case is sensitivity to interest rates and credit markets, lumpy reported earnings, long-tail insurance liabilities, and modest top-line growth. Weigh both against your own portfolio and needs.
What does MetLife actually do?
+
MetLife is one of the world's largest life insurers and employee-benefits companies. It sells group life, disability, and dental coverage through employers, retirement and income products like annuities and pension risk transfers, and life and health insurance across Asia, Latin America, and other regions. It earns money both by underwriting insurance and by investing the premiums it collects.
Does MetLife pay a dividend?
+
Yes. MetLife pays a regular quarterly dividend and has a long history of returning capital to shareholders. In 2026 it raised the quarterly dividend by about 4.4% to $0.5925 per share and extended its buyback program. Income is a meaningful part of the investment case, but always check the latest declared dividend and current yield before assuming any payout.
Walnut is informational, not investment advice, and gives no verdict on MET. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.